p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc

Cancer Research

Volumn 57, Issue 1, 1997, Pages 176-182

  Han, Jia Wen ^a   Dionne, Cheryl A ^a   Kedersha, Nancy L ^a   Goldmacher, Victor S ^a  

^a Apoptosis Technology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DOXORUBICIN; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; FIBROBLAST; MUTANT; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE; DOWN-REGULATION; DOXORUBICIN; GENETIC VECTORS; PROTO-ONCOGENE PROTEINS C-MYC; RATS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031034762     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
2. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
3. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
4. 1 checkpoint dose not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
5. Petty, R. D., Cree, I. A., Sutherland, L. A., Hunter, E. M., Lane, D. P., Preece, P. E., and Andreotti, P. E. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochem. Biophys. Res. Commun., 199: 264-270, 1994.
6. Fan, S., El-Diery, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fomace, A. J., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 8: 307-318, 1994.
7. Bristow, R. G., Jang, A., Peacock, J., Chung, S., Benchimol, S., and Hill, R. P. Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV 16-E7 and/or activated H-ras. Oncogene, 9: 1527-1536, 1994.
8. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
9. Lee, J. M., and Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA, 90: 5742-5746, 1993.
10. Lotem, J., and Sachs, L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood, 52: 1092-1096, 1993.
11. Jung, M., Notarion, V., and Dritschilo, A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res., 52: 6390-6393, 1992.
12. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Vokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667-3669, 1993.
13. 1 phase arrest and p53 function in human tumor cells. Cancer Res., 55: 1842-1846, 1995.
14. Fan, S., Smith, M. L., Rivet, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., and O'Connor, P. M. Disruption of p53 function sensitizes brest cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
15. Labrecque, S., and Matlashewski, G. I. Viability of wild type p53-containing and p53-deficient tumor cells following anticancer treatment: the use of human papillomavirus E6 to target p53. Oncogene, 10: 387-392, 1995.
16. Biard, D. S. F., Rhun, Y. L., Duthu, A., Lefaix, J. L., May, E., and May, P. Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res., 54: 3361-3364. 1994.
17. Field, J. K., and Spandidos, D. A. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis. Anticancer Res., 10: 1-22, 1990.
18. Spencer, C. A., and Groudine, M. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res., 56: 1-48, 1991.
19. Askew, D. S., Ashmun, R. A., Simmons, B. C., and Cleveland, J. L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene, 6: 1915-1922, 1991.
20. Fanidi, A., Harrington, E. A., and Evan, G. I. Cooperative interaction between c-myc and Bcl-2 proto-oncogenes. Nature (Lond.), 359: 554-556, 1992.
21. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
22. Shi, Y., Glynn, J. M., Guilbert, L. J., Cotter, T. G., Bissonnette, P. R., and Green, D. R. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science (Washington DC), 257: 212-214, 1992.
23. Chen, H. C., Zhang, J., and Ling, C. C. Transfected c-myc and c-Ha-ras modulate radiation-induced apoptosis in rat embryo cells. Radiat. Res., 139: 307-315, 1994.
24. Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J., 13: 3286-3295, 1994.
25. Klefstrom, J., Västrik, I., Saksela, E., Valle, J., Eilers, M., and Alitalo, K. c-Myc induces cellular susceptibility to the cytotoxic action of TNF-α. EMBO J., 13: 5442-5450, 1994.
26. Lotem, J., and Sachs, L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth & Differ., 4: 41-47, 1993.
27. Hermeking, H., and Eick, D. Mediation of c-myc-induced apoptosis by p53. Science (Washington DC), 265: 2091-2093, 1994.
28. Wagner, A. J., Kokontis, J. M., and Hay, N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genet. Dev., 8: 2817-2830, 1994.
29. Hsu, B., Marin, M. C., El-Naggar, A. K., Stephens, L. C., Brisbay, S., and McDonnel, T. J. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene, 11: 175-179, 1995.
30. Sakamuro, D., Eviner, V., Elliott, K. J., Showe, L., White, E., and Prendergast, G. C. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene, 11: 2411-2418, 1995.
31. Farmer, G. E., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., and Prives, C. Wild-type p53 activates transcription in vitro. Nature (Lond.), 358: 83-86, 1992.
32. Kern, S., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinsler, K., and Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulaled gene expression. Science (Washington DC), 256: 827-832, 1992.
33. Shaulian, E., Zauberman, A., Ginsberg, D., and Oren, M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol., 12: 5581-5592, 1992.
34. Penn, L. J. Z., Brooks, M. W., Laufer, E. M., and Land, H. Negative autoregulation of c-myc transcription. EMBO J., 9: 1113-1121, 1990.
35. Morgenstern, J. P., and Land, H. Advanced mammalian gene transfer: high titer retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell lines. Nucleic Acids Res., 18: 3587-3596, 1990.
36. -/- mouse embryo fibroblasts. Oncogene. 13: 739-748, 1996.
37. Gannon, J. V., Greaves, R., Iggo, R., and Lane, D. P. Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO J., 9: 1595-1602, 1990.
38. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, pp. 7.39-7.52. Plainview, NY: Cold Spring Harbor Laboratory, 1989.
39. Shi, Y. F., Szalay, M. G., Paskar, L., Sahai, B. M., Boyer, M., Singh, B., and Green, D. R. Activation-induced cell death in T cell hybridomas is due to apoptosis: morphologic aspects and DNA fragmentation. J. Immunol., 144: 3326-3333, 1990.
40. White, E., Grodzicker, T., and Stillman, B. W. Mutations in the gene encoding the adenovirus early region 1B 19,000-molecular-weight antigen cause the degradation of chromosomal DNA. J. Virol., 52: 410-419, 1984.
41. Furth, E. F., Thilly, W. G., Penman, B. W., Liber, H. L., and Rand, W. M. Quantitative assay for mutation in diploid human lymphoblasts using microtiter plates. Anal. Biochem., 110: 1-8, 1981.
42. Goldmacher, V. S., Tinnel, N. L., and Nelson, B. C. Evidence that pinocytosis in lymphoid cells has a low capacity. J. Cell Biol., 102: 1312-1319, 1986.
43. Maltzman, W., and Czyzyk, L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol., 4: 1689-1694, 1984.
44. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
45. Fritsche, M., Haessler, C., and Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene, 8: 307-318, 1993.
46. Reisman, D., Elkind, N. B., Roy, B., Beamon, J., and Rotter, V. c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth & Differ., 4: 57-65, 1993.
47. Barak, Y., Juven, T., Haffner, R., and Oren, M. mdm2 expression is induced by wild-type p53 activity. EMBO J., 12: 461-468, 1993.
48. Otto, A., and Deppert, W. Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53. Oncogene, 8: 2591-2603, 1993.
49. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4: 42-46, 1993.
50. Wyllie, A. H, Kerr, J. F. R., and Currie, A. R. Cell death: the significance of apoptosis. Int. Rev. Cytol., 68: 251-306, 1980.
51. Haupt, Y., Rowan, S., Shaulian, E., Vousden, K. H., and Oren, M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev., 9: 2170-2183, 1995.
52. Salmon, S. E., Hamburger, A. W., Soehnlen, B., Dune, B. G. M., Alberts, D. S., and Moon, T. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N. Engl. J. Med., 295: 1321-1327, 1978.
53. Cook, J. A., and Mitchell, J. B. Viability measurements in mammalian cell systems. Anal. Biochem., 179: 1-7, 1989.
54. 2 delay. Cancer Res., 55: 1643-1648, 1995.
55. Murnane, J. P., and Schwartz, J. L. (1993) Cell checkpoint and radiosensitivity. Nature (Lond.), 365: 22, 1993.
56. Radford, I. R. p53 status, DNA double-strand break repair proficiency, and radiation response of mouse lymphoid and myeloid cell lines. Int J. Radiat. Biol., 66: 557-560, 1994.
57. Radford, I. R. Radiation response of mouse lymphoid and myeloid cell lines. Part I. Sensitivity to killing by ionizing radiation, rate of loss of viability, and cell type of origin. Int. J. Radiat. Biol., 65: 203-215, 1994.
58. Yin, D. X., and Schimke, R. T. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res., 55: 4922-4928, 1995.
59. Lock, R. B., and Stribinskiene, L. Dual modes of death induced by eloposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res., 56: 4006-4012, 1996.
60. Cults, S. M., Parsons, P. G., Sturm, R. A., and Phillips, D. R. Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase. J. Biol. Chem., 271: 5422-5429, 1991.
61. Haimovitz-Friedman, A., Kan, C-C., Ehleiter, D., Persaud, R. S., McLoughlin, M., Fuks, Z., and Kolesnick, R. N. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. Exp. Med., 180: 525-535, 1994.
62. Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z., and Kolesnick, R. N. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell, 82: 405-414, 1995.